Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib and Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer
NCT04460937Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in esophageal cancer and gastroesophageal junction cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Number of Adverse Events at 6 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04460937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460937.